Stock Pick

Earnings preview: How do experts rate these blue-chip ASX stocks reporting this week?

Written by

openjargon

in

A woman smiles at the outlook she sees through binoculars.

Today marks the beginning of the second week of February’s earnings season. 

This week features several blue-chip ASX stocks that are set to release earnings results.

This includes: 

  • CSL Ltd (ASX: CSL) reports Wednesday 11 February
  • Commonwealth Bank of Australia (ASX: CBA) reports Wednesday 11 February
  • Pro Medicus Ltd (ASX: PME) reports Thursday 12 February
  • Cochlear Ltd (ASX: COH) reports Friday 13 February

Earnings season can bring heightened volatility as investors react – positively or negatively – to full or half-year results. 

With that in mind, here is what experts are saying about these blue-chip ASX stocks. 

Reason for optimism for these ASX stocks?

CSL shares are trading close to its 52-week low right now. The general consensus seems to be the current share price is an attractive entry point according to experts. 

It closed trading last week at $180.50. 

This ASX stock is down more than 30% over the last 12 months. It remains one of the top 10 largest companies on the ASX by market capitalisation.

Recent analysis from Canaccord Genuity said it is trading at a forward P/E of 17.5x – its lowest in 10 years. 

Morgan Stanley recently put an overweight rating and $242.00 price target on its shares.

This would indicate an upside of roughly 34%. 

The company reports its HY26 on Wednesday, which could spark movement depending on the results. 

It’s worth noting that this ASX stock crashed 15.9% in October last year after management reduced the company’s full-year FY 2026 guidance.

Another ASX stock drawing optimism ahead of earnings results is Pro Medicus. 

Sentiment for this blue-chip healthcare company indicates it is now undervalued. 

Its share price has fallen more than 44% in the last 12 months, closing last week at $157.62. 

Bell Potter currently has a buy rating and a $320.00 price target.

That indicates more than 100% upside. 

Mixed reviews 

CBA shares have shown some signs of life in the last week or so, rising 4% in that span. 

It closed last week at $158.91. 

Opinions remained mixed on this ASX banking giant.

The argument against CBA shares seems to always remain the same – it looks expensive. 

However Australia’s largest bank and second largest company could be a buy ahead of earnings results. 

It has now retreated significantly since passing $190 a share last June. 

Trying to time the market to perfection can be futile, and now could be close to a fair entry point. 

According to investment firm Wilsons, the upcoming result is expected to confirm that underlying sector fundamentals remain in good shape.

On the bearish side, Morgans estimates still suggest the stock is well overvalued. 

The broker has a price target on CBA shares under $100. 

Wait and see

For Cochlear shares, experts are suggesting a cautious approach before the company reports on Friday. 

It is currently trading almost 17% below their 52-week high.

Management has delivered three successive downgrades, driven by its services segment, which is reason for caution heading into its result.

However if the share price retreats further on Friday, it could land at an attractive buying opportunity. 

The post Earnings preview: How do experts rate these blue-chip ASX stocks reporting this week? appeared first on The Motley Fool Australia.

Should you invest $1,000 in Commonwealth Bank of Australia right now?

Before you buy Commonwealth Bank of Australia shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Commonwealth Bank of Australia wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys…

See the 5 Stocks

* Returns as of 1 Jan 2026

.custom-cta-button p {
margin-bottom: 0 !important;
}

More reading

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Cochlear. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended CSL, Cochlear, and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More posts